keyword
https://read.qxmd.com/read/38439804/the-role-of-modern-parameters-and-their-relationship-with-recurrence-risk-as-assessed-by-oncotype-dx-real-world-evidence
#21
JOURNAL ARTICLE
Dana Narvaez, Jorge Nadal, Adrian Nervo, Victoria Costanzo, Claudio Paletta, Fernando Petracci, Sergio Rivero, Alexis Ostinelli, Federico Coló, Loza Martín, Veronica Fabiano, Luciana Sabatini, Azul Perazzolo, Mora Amat, Matias Chacon, Federico Waisberg
Genomic analysis through various platforms is an essential tool for determining prognosis and treatment in a significant subgroup of early-stage breast cancer patients with hormone receptor-positive and human epidermal growth factor receptor 2 (HER2)-negative status. Additionally, combined clinical and pathological characteristics can accurately predict the recurrence score (RS), as demonstrated by the University of Tennessee risk nomogram. In this study, we aimed to identify classical clinical-pathological factors associated with high RS in a local population, including modern parameters such as current abemaciclib treatment recommendations, HER2-low status, different Ki-67 cutoff values, and samples obtained from secondary primary tumours...
2024: Ecancermedicalscience
https://read.qxmd.com/read/38438841/mmp-11-expression-in-early-luminal-breast-cancer-associations-with-clinical-mri-pathological-characteristics-and-disease-free-survival
#22
JOURNAL ARTICLE
Sébastien Molière, Massimo Lodi, Suzanne Leblanc, Anne Gressel, Carole Mathelin, Fabien Alpy, Marie-Pierre Chenard, Catherine Tomasetto
BACKGROUND: Early hormone-positive breast cancers typically have favorable outcomes, yet long-term surveillance is crucial due to the risk of late recurrences. While many studies associate MMP-11 expression with poor prognosis in breast cancer, few focus on early-stage cases. This study explores MMP-11 as an early prognostic marker in hormone-positive breast cancers. METHODS: In this retrospective study, 228 women with early hormone-positive invasive ductal carcinoma, treated surgically between 2011 and 2016, were included...
March 4, 2024: BMC Cancer
https://read.qxmd.com/read/38431780/treatment-and-prognosis-of-male-breast-cancer-a-multicentric-retrospective-study-over-11-years-in-the-czech-republic
#23
JOURNAL ARTICLE
Zuzana Bielcikova, Milos Holanek, Iveta Selingerova, Ondrej Sorejs, Iveta Kolarova, Renata Soumarova, Jan Proks, Lucie Reifova, Vlastimila Cmejlova, Lenka Linkova, Michaela Zabojnikova, Martina Chodacka, Lucie Janovska, Lenka Lisnerova, Karolina Kasparova, Denisa Pohankova, Lubos Petruzelka
PURPOSE: Male breast cancer (MBC) is a rare, but increasingly common disease, and lacks prospective studies. Collaborative efforts are needed to understand and address MBC, including its prognosis, in different countries. METHODS: We retrospectively reviewed the clinical, histopathological, and molecular-genetic characteristics, treatments, and survival outcomes of MBC diagnosed between 2007 and 2017 in the Czech Republic. Prognostic factors of overall survival (OS), recurrence-free interval (RFi), and breast cancer-specific mortality (BCSM) were analyzed and indirectly compared to international data...
March 2, 2024: Oncologist
https://read.qxmd.com/read/38423947/correlation-between-quantitative-parameters-obtained-by-dual-energy-spectral-ct-and-prognostic-histopathological-factors-and-biomarkers-in-breast-cancer
#24
JOURNAL ARTICLE
Nurgül Orhan Metin, Sinan Balcı, Yavuz Metin, Filiz Taşçı, Melih Gaffar Gözükara
RATIONALE AND OBJECTIVES: To investigate the correlation between quantitative parameters obtained by dual energy spectral computed tomography (DESCT) and various histopathological factors and biomarkers associated with the prognosis of breast cancer. MATERIALS AND METHODS: Quantitative parameters such as iodine content (IC), normalized IC (nIC), iodine enhancement (IE) and normalized IE (nIE) were measured on virtual monochromatic images and iodine mapping images obtained from DESCT in 116 female breast cancer patients...
February 1, 2024: Clinical Breast Cancer
https://read.qxmd.com/read/38412576/a-deep-learning-based-holistic-diagnosis-system-for-immunohistochemistry-interpretation-and-molecular-subtyping
#25
JOURNAL ARTICLE
Lin Fan, Jiahe Liu, Baoyang Ju, Doudou Lou, Yushen Tian
BACKGROUND: Breast cancer in different molecular subtypes, which is determined by the overexpression rates of human epidermal growth factor receptor 2 (HER2), estrogen receptor (ER), progesterone receptor (PR), and Ki67, exhibit distinct symptom characteristics and sensitivity to different treatment. The immunohistochemical method, one of the most common detecting tools for tumour markers, is heavily relied on artificial judgment and in clinical practice, with an inherent limitation in interpreting stability and operating efficiency...
February 26, 2024: Neoplasia: An International Journal for Oncology Research
https://read.qxmd.com/read/38388422/synchronous-double-primary-small-cell-lung-cancer-and-invasive-ductal-breast-carcinoma-a-case-report
#26
JOURNAL ARTICLE
Junqing Gan, Meiyue Liu, Fei Liu, Junxiu Wen, Wenjuan Fu, Jinghao Jia
BACKGROUND: Although lung and breast cancers are common malignancies, the occurrence of primary synchronous neoplasms involving these organs has been rarely reported in literature. CASE PRESENTATION: A 75-year-old female patient presented at a local hospital with a ten-day history of dizziness and slurred speech. A CT contrast-enhanced scan revealed a 4.2 cm mass in the lower lobe of the right lung and a 3.8 cm space-occupying lesion in the right breast...
February 22, 2024: BMC Pulmonary Medicine
https://read.qxmd.com/read/38383139/increased-pi3k-pathway-activity-is-associated-with-recurrent-breast-cancer-in-patients-with-low-and-intermediate-21-gene-recurrence-score
#27
JOURNAL ARTICLE
Lawrence Hsu Lin, Yvonne Wesseling-Rozendaal, Varshini Vasudevaraja, Guomiao Shen, Margaret Black, Dianne van Strijp, Sigi Neerken, Paul A van de Wiel, George Jour, Paolo Cotzia, Farbod Darvishian, Matija Snuderl
AIMS: We investigated key signalling pathways' activity and mutational status of early-stage breast carcinomas with low and intermediate 21-gene recurrence score (RS) to identify molecular features that may predict recurrence. METHODS: This is a retrospective case-control study of 18 patients with recurrent breast carcinoma with low and intermediate 21-gene RS (<25) and control group of 15 non-recurrent breast cancer patients. DNA and mRNA were extracted from tumour tissue...
February 21, 2024: Journal of Clinical Pathology
https://read.qxmd.com/read/38381204/vimentin-protein-is-a-factor-for-decreasing-breast-cancer-cell-proliferation-co-culture-with-human-bone-marrow-derived-mesenchymal-stem-cells-pre-treated-with-thiazolidinedione-solutions
#28
JOURNAL ARTICLE
Lim Shern Kwok, Shim Siang Yian, Layla Qasim Ismael, Yvonne Tee Get Bee, Gam Lay Harn, Khoo Boon Yin
BACKGROUND: Our previous study investigated the levels of soluble growth factors in the conditioned media of bone marrow-derived mesenchymal stem cells (BMSCs) pre-treated with thiazolidinedione solutions. The present study aimed to investigate the complex intracellular proteins extracted from BMSCs pre-treated with pioglitazone and/or rosiglitazone using proteomics. METHODS: The proliferative effect of the identified protein on MCF-7 cells that interacted non-adhesively with BMSCs pre-treated with pioglitazone and/or rosiglitazone was evaluated using cell culture inserts and conditioned media...
February 21, 2024: Molecular Biology Reports
https://read.qxmd.com/read/38379328/somatic-mutations-in-a-multigene-panel-and-impact-on-prognosis-based-on-tp53-status-in-chinese-her2-positive-patients-undergoing-neoadjuvant-therapy-a-single-institution-retrospective-cohort
#29
JOURNAL ARTICLE
Min Xiong, Xuliren Wang, Douwaner Liu, Bingqiu Xiu, Qi Zhang, Weiru Chi, Chih Wan Goh, Liyi Zhang, Ming Chen, Hengyu Ren, Zhi-Ming Shao, Benlong Yang, Jiong Wu
BACKGROUND: Gene mutations play a crucial role in the occurrence and development of tumors, particularly in breast cancer (BC). Neoadjuvant therapy (NAT) has shown greater clinical benefit in HER2-positive breast cancer. However, further clinical investigation is needed to fully understand the correlation between genetic mutations and NAT efficacy and the long-term prognosis in HER2-positive BC. METHODS: This was a retrospective cohort study of 222 patients receiving NAT between 2017 and 2021 in the Department of Breast Surgery of Fudan University Shanghai Cancer Center...
January 2024: Cancer Medicine
https://read.qxmd.com/read/38376268/tumor-budding-in-breast-carcinoma-a-systematic-review-and-meta-analysis
#30
JOURNAL ARTICLE
Archana Buch, Uzair Khan, Hetal Rathod, Khushi Jain, Aryan Dwivedi, Arasi Rajesh
Tumor budding is gaining importance as a prognostic factor in various carcinomas due to its association with epithelial-mesenchymal transition (EMT) and hence clinical outcome. Reporting tumor budding in breast cancer lacks homogeneity. We aim to systematically review the existing literature and conduct a meta-analysis to assess the prognostic implication of tumor budding in breast carcinoma. A systematic search was performed to identify studies that compared different prognostic variables between high- and low-grade tumor budding...
October 1, 2023: Journal of Cancer Research and Therapeutics
https://read.qxmd.com/read/38370397/a-modular-microfluidic-platform-to-study-how-fluid-shear-stress-alters-estrogen-receptor-phenotype-in-er-breast-cancer-cells
#31
JOURNAL ARTICLE
Braulio Andrés Ortega Quesada, Jonathan Cuccia, Rachael Coates, Blake Nassar, Ethan Littlefield, Elizabeth C Martin, Adam T Melvin
Metastatic breast cancer leads to poor prognoses and worse outcomes in patients due to its invasive behavior and poor response to therapy. It is still unclear what biophysical and biochemical factors drive this more aggressive phenotype in metastatic cancer; however recent studies have suggested that exposure to fluid shear stress in the vasculature could cause this. In this study a modular microfluidic platform capable of mimicking the magnitude of fluid shear stress (FSS) found in human vasculature was designed and fabricated...
2024: Microsystems & Nanoengineering
https://read.qxmd.com/read/38368871/neoadjuvant-chemotherapy-and-pathologic-complete-response-in-hr-her2-breast-cancer-impact-of-tumor-ki67-and-er-status
#32
JOURNAL ARTICLE
Goncagul Akdag, Sedat Yildirim, Akif Dogan, Zeynep Yuksel Yasar, Hamit Bal, Oguzcan Kinikoglu, Sila Oksuz, Ugur Ozkerim, Salih Tunbekici, Hacer Sahika Yildiz, Ezgi Turkoglu, Ozkan Alan, Sermin Coban Kokten, Deniz Isik, Ozlem Nuray Sever, Hatice Odabas, Mahmut Emre Yildirim, Nedim Turan
INTRODUCTION: Neoadjuvant chemotherapy (NAC) is extensively employed in breast cancer (BC), primarily for aggressive subtypes like triple-negative and human epidermal growth factor receptor 2 (HER2) positive BC, and in estrogen receptor-positive (ER+)/ HER2- BC with high-risk features. In ER+/HER2- breast cancer, pathological complet rates are much lower (<10%), while axillary dissection rates are higher. This study focuses on hormone receptor positive (HR+)/HER2- BC patients undergoing NAC, examining its impact on pathological complete response (pCR) rates, with specific attention to tumor Ki67 and ER status...
February 16, 2024: Chemotherapy
https://read.qxmd.com/read/38367549/anti-metastatic-effects-of-ags-30-on-breast-cancer-through-the-inhibition-of-m2-like-macrophage-polarization
#33
JOURNAL ARTICLE
Jingjing Li, Zhuyun Liu, Xiaoping Wu, Simon Ming-Yuen Lee, Sai-Wang Seto, Jinming Zhang, Guo-Chun Zhou, George Pak-Heng Leung
AGS-30, a new andrographolide derivative, showed significant anticancer and anti-angiogenic characteristics. However, its role in controlling macrophage polarization and tumor immune response is unknown. Thus, the main goals of this study are to investigate how AGS-30 regulates macrophage polarization and how it suppresses breast cancer metastasis. AGS-30 inhibited IL-4 and IL-13-induced RAW 264.7 and THP-1 macrophages into M2-like phenotype. However, AGS-30 did not affect the LPS and IFN-γ-induced polarization of M1-like macrophages...
February 16, 2024: Biomedicine & Pharmacotherapy
https://read.qxmd.com/read/38362377/rational-and-trial-design-of-fascinate-n-a-prospective-randomized-precision-based-umbrella-trial
#34
JOURNAL ARTICLE
Wen-Jia Zuo, Li Chen, Yu Shen, Zhong-Hua Wang, Guang-Yu Liu, Ke-Da Yu, Gen-Hong Di, Jiong Wu, Jun-Jie Li, Zhi-Ming Shao
BACKGROUND: With our growing insight into the molecular heterogeneity and biological characteristics of breast cancer, individualized treatment is the future of cancer treatment. In this prospective Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series study - neoadjuvant therapy (FASCINATE-N) trial, we classify breast cancer patients using multiomic characteristics into different subtypes to evaluate the efficacy of precision-based targeted therapies compared to standard neoadjuvant chemotherapy...
2024: Therapeutic Advances in Medical Oncology
https://read.qxmd.com/read/38351793/asynchronous-bilateral-male-breast-cancer-a-rare-case-report
#35
JOURNAL ARTICLE
Teodor Aleksiev, Zlatina Ivanova, Hristo Dobrev
We describe a rare case of asynchronous bilateral carcinoma of the mammary glands in a 66-year-old man. The patient was admitted to the Department of Dermatology and Venereology due to exacerbation of chronic eczema. During the examination, a 3×2-cm tumor with retraction of the mammilla was found in the right mammary gland. Mastectomy and regional lymphatic dissection were performed. Histological examination showed invasive ductal carcinoma, ER (+) 70%, PR (-), HER2 (-). Treatment included chemotherapy, radiotherapy, and hormone therapy...
December 31, 2023: Folia Medica
https://read.qxmd.com/read/38349444/distinct-profiles-of-proliferating-cd8-tcf1-t-cells-and-cd163-pd-l1-macrophages-predict-risk-of-relapse-differently-among-treatment-na%C3%A3-ve-breast-cancer-subtypes
#36
JOURNAL ARTICLE
Konstantinos Ntostoglou, Sofia D P Theodorou, Tanja Proctor, Ilias P Nikas, Sinclair Awounvo, Athanasia Sepsa, Vassilis Georgoulias, Han Suk Ryu, Ioannis S Pateras, Christos Kittas
Immunophenotypic analysis of breast cancer microenvironment is gaining attraction as a clinical tool improving breast cancer patient stratification. The aim of this study is to evaluate proliferating CD8 + including CD8 + TCF1 + Τ cells along with PD-L1 expressing tissue-associated macrophages among different breast cancer subtypes. A well-characterized cohort of 791 treatment-naïve breast cancer patients was included. The analysis demonstrated a distinct expression pattern among breast cancer subtypes characterized by increased CD8 + , CD163 + and CD163 + PD-L1 + cells along with high PD-L1 status and decreased fraction of CD8 + Ki67 + T cells in triple negative (TNBC) and HER2 + compared to luminal tumors...
February 13, 2024: Cancer Immunology, Immunotherapy: CII
https://read.qxmd.com/read/38344331/mammographic-assessment-of-breast-density-as-a-tool-for-predicting-the-response-to-neoadjuvant-therapy-in-breast-cancer-patients
#37
JOURNAL ARTICLE
Lorena Alexandra Lisencu, Andrei Roman, Andrei Paşca, Alexandru Irimie, Cosmin Lisencu, Mircea Negrutiu, Bogdan Fetica, Andrei Cismaru, Ovidiu Balacescu, Oana Tudoran, Carmen Lisencu
BACKGROUND AND AIMS: Breast cancer (BC) is the most frequently diagnosed cancer and the leading cause of cancer-related death among women worldwide. For locally advanced diseases and high-risk tumors, neoadjuvant therapy (NAT) is the treatment of choice. Some studies show that mammographic density (MD) tumor margins and the presence of microcalcifications play a prognostic role in BC patients. Hence, the objective of this retrospective study was to assess if MD could predict the response to NAT among different molecular subtypes of BC patients undergoing NAT at The "Prof...
January 2024: Medicine and pharmacy reports
https://read.qxmd.com/read/38341511/organoid-forming-potential-as-complementary-parameter-for-accurate-evaluation-of-breast-cancer-neoadjuvant-therapeutic-efficacy
#38
JOURNAL ARTICLE
Hai-Shan Ye, Dan Zhou, Hong Li, Jin Lv, Hui-Qi Huang, Jia-Jun She, Jun-Hua Nie, Ting-Ting Li, Meng-Di Lu, Bo-Le Du, Shu-Qing Yang, Pei-Xian Chen, Sheng Li, Guo-Lin Ye, Wei Luo, Jia Liu
BACKGROUND: 13-15% of breast cancer/BC patients diagnosed as pathological complete response/pCR after neoadjuvant systemic therapy/NST suffer from recurrence. This study aims to estimate the rationality of organoid forming potential/OFP for more accurate evaluation of NST efficacy. METHODS: OFPs of post-NST residual disease/RD were checked and compared with clinical approaches to estimate the recurrence risk. The phenotypes of organoids were classified via HE staining and ER, PR, HER2, Ki67 and CD133 immuno-labeling...
February 10, 2024: British Journal of Cancer
https://read.qxmd.com/read/38337775/discordance-of-biomarker-expression-profile-between-primary-breast-cancer-and-synchronous-axillary-lymph-node-metastasis-in-preoperative-core-needle-biopsy
#39
JOURNAL ARTICLE
Stefano Marletta, Alexandra Giorlandino, Enrico Cavallo, Michele Dello Spedale Venti, Giorgia Leone, Maria Grazia Tranchina, Lucia Gullotti, Claudia Lucia Bonanno, Graziana Spoto, Giusi Falzone, Irene Tornabene, Carmelina Trovato, Marco Maria Baron, Giuseppe Di Mauro, Lucia Falsaperna, Giuseppe Angelico, Sarah Pafumi, Antonio Rizzo
Background : Breast cancer (BC) is a heterogeneous disease made up of clones with different metastatic potential. Intratumoral heterogeneity may cause metastases to show divergent biomarker expression, potentially affecting chemotherapy response. Methods : We investigated the immunohistochemical (IHC) and FISH profile of estrogen receptors (ER), progesterone (PR) receptors, Ki67, and HER2 in a series of BC-matched primary tumors (PTs) and axillary lymph node (ALN) metastases in pre-operative core needle biopsies (CNBs)...
January 25, 2024: Diagnostics
https://read.qxmd.com/read/38337757/comprehensive-and-accurate-molecular-profiling-of-breast-cancer-through-mrna-expression-of-esr1-pgr-erbb2-mki67-and-a-novel-proliferation-signature
#40
JOURNAL ARTICLE
Anne-Sophie Wegscheider, Joanna Gorniak, Sara Rollinson, Leanne Gough, Navdeep Dhaliwal, Agustin Guardiola, Anna Gasior, Denise Helmer, Zoe Pounce, Axel Niendorf
BACKGROUND: An accurate status determination of breast cancer biomarkers (ER, PR, HER2, Ki67) is crucial for guiding patient management. The "gold standard" for assessing these biomarkers in FFPE tissue is IHC, which faces challenges in standardization and exhibits substantial variability. In this study, we compare the concordance of a new commercial RT-qPCR kit with IHC in determining BC biomarker status. METHODS: The performance was evaluated using 634 FFPE specimens, which underwent histological analysis in accordance with standard of care methods...
January 23, 2024: Diagnostics
keyword
keyword
72753
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.